CLINICAL_TRIALS
trial_result
· 2011-10-17
Clinical Trial Update: Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study [Phase 2]
Summary
Phase 2 clinical trial update of a GABA-A Alpha2/3 selective agent in schizophrenia; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: University of Pittsburgh | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2011-10-17